Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satisfaction and Impact of Combined Facial Treatment (HARMONY)
NCT04609020Phase 4Completed
- Sponsor
- Allergan
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of onabotulinumtoxinA in facial rhytides, Skin aging, sponsored by Allergan. Started Feb 2023; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
facial rhytidesSkin aging
Beyond the preview
Go deeper on NCT04609020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609020.